Ocular Therapeutix Inc. diskutieren

$ Ocul eingeleitet mit einem Übergewicht bei Cantor. $ 35 PT

hat

Ocur looks significantly undervalued,

given the likelihood of approval and potential of Dextenza. The company also has several other compounds in development. The company ended 2016 with just under $70 million in cash on hand and has a quarterly burn rate of less than $10 million. The shares currently sell for approximately one third the median analyst price target and I would not be surprised if the shares run up into that all-important July PDUFA date.

klostergang stimmt der Buy-Einschätzung von tamam zu

SecteurEquipement, fournitures et distribution médicale Agenda 14/11 Publication de résultats

Develops and commercializes therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Secteur Equipement, fournitures et distribution médicale Agenda 08/05 Publication de résultats

Ocular Therapeutix, Inc. est une société biopharmaceutique pour le développement, la fabrication et la commercialisation de thérapies pour les maladies et les affections de la plateforme technologique exclusive d’hydrogel. DEXTENZA (insert de dexaméthasone) à usage intracanaliculaire, phase de développement clinique de phase III pour le traitement de la douleur et l'inflammation oculaire après chirurgie ophtalmologique. OTX-TP (insert travoprost) est en phase III de développement clinique pour le glaucome et l’hypertension oculaire. OTX-TIC, une injection intracamérale de travoprost à libération prolongée pour le traitement du glaucome modéré et de l'hypertension oculaire, as that in injections in a prolated prolated for treatment des maladies rétiniennes. Ces injections comprennent le développement d'OTX-TKI, un inhibiteur de tyrosine kinase, et, en collaboration avec Regeneron, un facteur de croissance endothélial anti-vasculaire à libération prolongée.

Nombre d'employés

: 119 personnes.

stratec stimmt dem Sentiment von 'Buy' zu

Over the weekend, JMP Securities reteirated their Buy rating and $9 price target on Ocular Therapeutix  JMP's analyst noted 'the FDA approved Dextenza's sNDA for treating ocular inflammation following
ophthalmic surgery, roughly five months earlier than expected. He believes Dextenza will launch with both pain and inflammation indications and forecasts about $12 million of Dextenza sales in 2019, with a majority coming in the fourth quarter. Ocular has been "firing on all cylinders" since Dextenza was approved for both pain and inflammation and securing a C-code and a T-code'